Combination Therapy in Experimental and Clinical Candidosis

  • A. Polak
Part of the Federation of European Microbiological Societies Symposium Series book series (FEMS, volume 50)


Antimycotic chemotherapy for deep-seated candidosis in patients with reduced immune-defense is still a problem. Only a few antimycotics are available for systemic use and all have their limitations. Thus, interest in drug combinations is increasing in the hope of improving the efficacy and the spectrum of antimycotic therapy.


Candida Infection Triple Combination Heroin Addict Ergosterol Biosynthesis Triazole Derivative 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Polak, H.J. Scholer, M. Wall, Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice, Chemotherapy, 28: 461 (1982).PubMedCrossRefGoogle Scholar
  2. 2.
    A. Polak: Synergism of polyene antibiotics with 5-fluorocytosine, Chemotherapy, 24: 2 (1978).PubMedCrossRefGoogle Scholar
  3. 3.
    A. Polak,: Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice, Chemotherapy, 33: 381 (1987).PubMedCrossRefGoogle Scholar
  4. 4.
    A. Polak, 5- Fluorocytosine et associations, Ann.Biol.Clin., 45: 669 (1987).Google Scholar
  5. 5.
    A. Polak and A. Schaffner, Association des antifongiques dans les mycoses experimentales, Med.Mal.Inf., 14: 553 (1980).CrossRefGoogle Scholar
  6. 6.
    A. Schaffner and P.G. Frick, The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis, J.Infect.Dis., 151: 902 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    J.E. Bennett, W.E. Dismukes, R.J. Duma, G. Medoff, M.A. Sande et al., A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis, New Engl. J.Med., 301: 127 (1979).Google Scholar
  8. 8.
    A. Polak, Combined therapy of systematic mycoses, in: Proc. 13th Intern. Congr. Chemother., Vienna 1983, K.H.Spitzy and K.Karrer, eds., Symposia 49/1 and 49/2, part 20, pp. 2–9, H.Egermann, Vienna (1983).Google Scholar
  9. 9.
    J.E. Bennett, R.M. Kliegman, A.A. Fanaroff, Disseminated fungal infections in very lowbirth-weight infants: therapeutic toxicity, Pediatrics, 73: 153 (1984).Google Scholar
  10. 10.
    R.G. Faix, Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement, J.Pediatr., 105: 616 (1984).PubMedCrossRefGoogle Scholar
  11. 11.
    D. Armstrogn, Problems in the management of opportunistic fungal infections, 9th Ian Murray Memorial Lecture, Brit.Soc.Mycopathol. (1986).Google Scholar
  12. 12.
    J.W.M. Gold, Opportunistic fungal infections in patients with neo-plastic disease, Am.J.Med., 76: 458 (1984).PubMedCrossRefGoogle Scholar
  13. 13.
    E. Haron, R. Feld, P. Tuffnell, B. Patterson, R. Hasselback, A. Matlow, Hepatic candidiasis: an increasing problem in immunocompromised patients, Am.J.Med., 83: 17 (1987).PubMedCrossRefGoogle Scholar
  14. 14.
    D. Dupont and E.E. Drouhet, Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts, new clinical and therapeutic aspects in 38 patients. J.Infect.Dis., 152: 577 (1985).PubMedCrossRefGoogle Scholar
  15. 15.
    M.A. Viviani and A.M. Tortorano, Management of cryptococcosis in AIDS patients, Xth Congr. ISHAM, Barcelona 1988, poster N.RT17–1.Google Scholar
  16. 16.
    D. Borelli, A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis, Rev.Infect.Dis., 9 (Suppl. 1) 557 (1987).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • A. Polak
    • 1
  1. 1.F. Hoffmann-La Roche & Co., Ltd.BaselSwitzerland

Personalised recommendations